Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Actinogen Medical ( (AU:ACW) ).
Actinogen Medical has called a general meeting of shareholders to be held in person in Sydney on 23 June 2026, with meeting materials and proxy voting available online through its investor and registry platforms. The company is also urging investors to adopt paperless communications via its designated registry provider as it modernises its shareholder engagement processes.
The update reiterates Actinogen’s clinical focus on Xanamem, its lead candidate for Alzheimer’s disease and depression, highlighting ongoing Phase 2b/3 and open-label extension trials in Alzheimer’s patients and previously reported positive Phase 2a results in treatment-resistant depression. These developments underscore Actinogen’s bid to strengthen its position in the neurodegenerative and neuropsychiatric therapeutics market, with upcoming trial readouts expected to be a key catalyst for stakeholders.
The most recent analyst rating on (AU:ACW) stock is a Buy with a A$0.08 price target. To see the full list of analyst forecasts on Actinogen Medical stock, see the AU:ACW Stock Forecast page.
More about Actinogen Medical
Actinogen Medical is an ASX-listed biotechnology company developing Xanamem, a first-in-class oral therapy targeting neurological and neuropsychiatric diseases linked to dysregulated brain cortisol, including Alzheimer’s disease and depression. The company focuses on substantial unmet medical needs where cortisol-driven cognitive dysfunction and neuropsychiatric symptoms are debilitating for patients.
Average Trading Volume: 2,871,369
Technical Sentiment Signal: Sell
Current Market Cap: A$122.1M
Find detailed analytics on ACW stock on TipRanks’ Stock Analysis page.